198 related articles for article (PubMed ID: 15120772)
1. The bioavailability of morphine applied topically to cutaneous ulcers.
Ribeiro MD; Joel SP; Zeppetella G
J Pain Symptom Manage; 2004 May; 27(5):434-9. PubMed ID: 15120772
[TBL] [Abstract][Full Text] [Related]
2. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML
Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664
[TBL] [Abstract][Full Text] [Related]
3. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
5. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
6. Achieving analgesia for painful ulcers using topically applied morphine gel.
Tran QN; Fancher T
J Support Oncol; 2007 Jun; 5(6):289-93. PubMed ID: 17624054
[No Abstract] [Full Text] [Related]
7. Study to determine the efficacy of topical morphine on painful chronic skin ulcers.
Vernassiere C; Cornet C; Trechot P; Alla F; Truchetet F; Cuny JF; Commun N; Granel Brocard F; Barbaud A; Schmutz JL
J Wound Care; 2005 Jun; 14(6):289-93. PubMed ID: 15974417
[TBL] [Abstract][Full Text] [Related]
8. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of a morphine suppository is increased after intracolostomal administration in colostoma-constructed rabbits.
Nagasawa K; Kintsuji S; Nakanishi H; Nagai K; Fujimoto S
Int J Pharm; 2003 Oct; 265(1-2):65-73. PubMed ID: 14522119
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
Perreault S; Choinière M; du Souich PB; Bellavance F; Beauregard G
Ann Pharmacother; 2001 Dec; 35(12):1588-92. PubMed ID: 11793627
[TBL] [Abstract][Full Text] [Related]
13. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.
Hunt A; Joel S; Dick G; Goldman A
J Pediatr; 1999 Jul; 135(1):47-55. PubMed ID: 10393603
[TBL] [Abstract][Full Text] [Related]
16. Morphine in intrasite gel applied topically to painful ulcers.
Zeppetella G; Ribeiro MD
J Pain Symptom Manage; 2005 Feb; 29(2):118-9. PubMed ID: 15733803
[No Abstract] [Full Text] [Related]
17. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
[TBL] [Abstract][Full Text] [Related]
18. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
Goucke RC; Hackett PL; Ilett KF
Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management.
Smith MT; Wright AW; Williams BE; Stuart G; Cramond T
Anesth Analg; 1999 Jan; 88(1):109-16. PubMed ID: 9895076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
